Loading
A phase 2 trial of Fluoroestradiol F-18 in Breast cancer, run by National Cancer Institute (NCI), active and no longer recruiting.
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy is a phase 2 interventional study registered as NCT02398773 by National Cancer Institute (NCI), with 99 participants planned, started 2016-05-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory Biomarker Analysis, Positron Emission Tomography. Conditions recorded: HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7.
Linked to the drug Fluoroestradiol F-18 because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/